Red cell distribution wide (RDW) as severity biomarker in patients with community-adquired pneumonia (CAP)

S. Fandos, E. Minchole, A. Simon, C. Panadero, A. Lasierra, G. Hernandez, C. Lapresta, S. Bello (Zaragoza, Spain)

Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Session: Scores, biomarkers and risk factors in respiratory infections
Session type: Thematic Poster Session
Number: 2503
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Fandos, E. Minchole, A. Simon, C. Panadero, A. Lasierra, G. Hernandez, C. Lapresta, S. Bello (Zaragoza, Spain). Red cell distribution wide (RDW) as severity biomarker in patients with community-adquired pneumonia (CAP). Eur Respir J 2012; 40: Suppl. 56, 2503

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Red cells distribution width as a potential biomarker in COPD.
Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics
Year: 2018

Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP)
Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders
Year: 2015


Red cell distribution width (RDW) as a biomarker of disease severity in ILD patients
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015

I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010

Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts)
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010


The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 241s
Year: 2004

COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012

Lymphocyte-to-Monocyte ratio (LMR) and Platelet-to-lymphocyte (PLR) ratio levels as a predictors of lung failure in severe Covid-19 pneumonia patients (pts)
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021


C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 805s
Year: 2006

Determination of community acquired pneumonia (CAP) severity in pregnant (pr.)
Source: Virtual Congress 2021 – Clinical features and challenges of COVID-19
Year: 2021


The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021


Red cell distribution width (RDW): A new predictor for chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012


Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010

The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014


Correlation of induced sputum (IS) particles size distribution (PDS) and pulmonary function test (PFT) in asthmatics patients (A-pts)
Source: Eur Respir J 2004; 24: Suppl. 48, 604s
Year: 2004

Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008


Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 641s
Year: 2005